Article Information
- Received October 17, 2016
- Revision received March 7, 2017
- Accepted March 8, 2017
- First published March 17, 2017.
- Version of record published April 19, 2017.
Author Information
- Aaron P. Schultz1,5,
- Jasmeer P. Chhatwal1,5,
- Trey Hedden2,5,
- Elizabeth C. Mormino1,5,
- Bernard J. Hanseeuw1,2,
- Jorge Sepulcre2,
- Willem Huijbers1,8,
- Molly LaPoint1,
- Rachel F. Buckley1,6,7,
- Keith A. Johnson2,3, and
- Reisa A. Sperling1,4
- 1Departments of Neurology and
- 2Radiology, and
- 3Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114,
- 4Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115,
- 5Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown HealthCare Center, Charlestown, Massachusetts 02129,
- 6Florey Institute of Neuroscience and Mental Health, Parkville 3052, Victoria, Australia, and
- 7Melbourne School of Psychological Sciences, University of Melbourne, Melbourne 3010, Victoria, Australia, and
- 8Jheronimus Academy of Data Science, Cognitive Science and Artificial Intelligence, Tilburg University, 5211 DA, 's-Hertogenbosch, The Netherlands
Author contributions
Author contributions: A.P.S., K.A.J., and R.S. designed research; A.P.S., J.P.C., T.H., B.J.H., M.L., K.A.J., and R.A.S. performed research; A.P.S., J.P.C., E.C.M., J.S., W.H., R.F.B., K.A.J., and R.A.S. analyzed data; A.P.S., J.P.C., T.H., E.C.M., B.J.H., J.S., W.H., M.L., R.F.B., K.A.J., and R.A.S. wrote the paper.
Disclosures
- Received October 17, 2016.
- Revision received March 7, 2017.
- Accepted March 8, 2017.
This work was supported in part by shared instrumentation grants and Grants S10OD010364, S10RR023401, and 1S10RR019307–01 from the Martinos Center for Biomedical Imaging. The research was also supported in major part by Harvard Aging Brain Study Grant P01-AG-036694. T.H. received funding from National Institutes of Health (NIH) Grants K01-AG-040197, P01-AG-036694, P50-AG-005134, R01-AG-053509, and R01-AG-034556. E.C.M. received funding from NIH Grant K01-AG-051718. B.J.H. received support from the Belgian American Education Foundation. J.S. received funding from HIH Grant K23EB019023. R.F.B. received funding from the Australian National Health and Medical Research Council and Australian Research Council Dementia Research Fellowship APP1105576. K.A.J. received funding from NIH Grants R01-EB-014894, R21-AG-038994, R01-AG-026484, R01-AG-034556, P50-AG-00513421, U19-AG-10483, P01-AG-036694, R13-AG-042201174210, R01-AG-027435, and R01-AG-037497; and Alzheimer's Association Grant ZEN-10–174210. R.A.S. has received research support from NIH Grants P01-AG-036694, U01-AG-032438, U01-AG-024904, R01-AG-037497, R01-AG-034556, K24-AG-035007, P50-AG-005134, U19-AG-010483, and R01-AG027435; Fidelity Biosciences; the Harvard NeuroDiscovery Center; and the Alzheimer's Association.
A.P.S. has been a paid consultant for Janssen Pharmaceuticals and Biogen. E.C.M. has served as a consultant for Biogen and has received research support from Eli Lilly and Janssen Pharmaceuticals. K.A.J. has served as paid consultant for Bayer, GE Healthcare, Janssen Alzheimer's Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie; is a site coinvestigator for Lilly/Avid, Pfizer, Janssen Immunotherapy, and Navidea; and has spoken at symposia sponsored by Janssen Alzheimer's Immunotherapy, and Pfizer. R.A.S. has served as a paid consultant for Abbvie, Biogen, Bracket, Genentech, Lundbeck, Roche, and Sanofi; has served as a coinvestigator for Avid, Eli Lilly, and Janssen Alzheimer Immunotherapy clinical trials; has spoken at symposia sponsored by Eli Lilly, Biogen, and Janssen; and has received research support from Janssen Pharmaceuticals and Eli Lilly (these relationships are not related to the content in the manuscript). The authors declare no other competing financial interests.
- Correspondence should be addressed to Dr. Reisa A. Sperling, Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, MA 02115. E-mail: reisa{at}bwh.harvard.edu
Other Version
- previous version (March 17, 2017).
- You are viewing the most recent version of this article.
Online Impact